Viventia’s Proxinium gets EU orphan drug status
The EMEA orphan drug designation for Proxinium, Viventia’s lead product candidate, follows the FDA’s decision to confer orphan status upon the drug for this indication in January. Proxinium
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.